Full history for every metric is available with a Kvantra account
XOMA Royalty Corp. (XOMA)
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 29 | 38 | 6 | 5 | 28 | 52 | 36 |
| Operating profit | $m | 11 | 5 | |||||
| Net profit | $m | 13 | 16 | -17 | -41 | -14 | 32 | 32 |
| EPS reported | $ | 1.46 | 1.57 | |||||
| Operating cashflow per share | $ | 0.16 | 0.56 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | 0.16 | 0.56 | |||||
| Free cash flow | $m | 3 | 7 | |||||
| Net debt | $m | 46 | 8 | |||||
| Book value equity | $m | 104 | 113 | |||||
| Book value per share | $ | 5.78 | 6.48 | |||||
| Number of shares | m | 17.98 | 17.42 | |||||
| DPS (TTM paid) | $ | 0.30 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | 18.21 | 25.59 | |||||
| P/B LTM | x | 4.60 | 4.46 | |||||
| P/S LTM | x | 9.17 | 13.90 | |||||
| P/FCF LTM | x | 166.54 | 75.94 | |||||
| EV/EBITDA LTM | x | 11.02 | 10.20 | |||||
| EV/Sales LTM | x | 10.10 | 14.12 | |||||
| Earnings Yield LTM | % | 5.49% | 3.91% | |||||
| FCF Yield | % | 0.60% | 1.32% | |||||
| Quality | ||||||||
| ROE | % | 30.50% | 30.21% | |||||
| ROIC | % | 4.49% | 1.94% | |||||
| Operating margin | % | 21.83% | 13.73% | |||||
| Gross margin | % | 94.30% | 93.29% | |||||
| FCF/Sales | % | 5.51% | 18.31% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +83.06% | -3.33% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 1.14% | 0.00% | |||||
| Dividend Growth | % | - | - | |||||
| Payout Ratio | % | 20.84% | 19.72% | |||||
| FCF/Debt | x | 0.02 | 0.05 | |||||
| Net Debt/EBITDA | x | 1.02 | 0.60 | |||||
| EBIT/Net interest | x | 0.87 | 0.38 | |||||
| Net debt/market cap | % | 9.66% | 1.56% | |||||
| Net debt/Equity | x | 0.44 | 0.07 | |||||
| Gross debt/equity | x | 1.27 | 1.10 | |||||
Company overview
XOMA Royalty Corp. functions as a specialist in aggregating biotechnology royalties, with its operations extending across Europe, the United States, and the Asia Pacific region. The company is dedicated to fostering advancements in human health by collaborating with biotechnology firms. Its core business model involves acquiring the anticipated future economic benefits, such as royalties and milestone payments, associated with pre-market therapeutic candidates that have already been licensed to pharmaceutical or biotechnology firms. The firm focuses its investments on early to mid-stage clinical assets, typically those in Phase 1 and 2 trials, selected for their robust commercial potential and because they are licensed to development partners. Its extensive portfolio currently encompasses around 70 distinct assets. The parent company, XOMA Corporation, established in 1981, has its main office in Emeryville, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
XOMA Royalty Corp. (XOMA)
XOMA Royalty Corp. functions as a specialist in aggregating biotechnology royalties, with its operations extending across Europe, the United States, and the Asia Pacific region. The company is dedicated to fostering advancements in human health by collaborating with biotechnology firms. Its core business model involves acquiring the anticipated future economic benefits, such as royalties and milestone payments, associated with pre-market therapeutic candidates that have already been licensed to pharmaceutical or biotechnology firms. The firm focuses its investments on early to mid-stage clinical assets, typically those in Phase 1 and 2 trials, selected for their robust commercial potential and because they are licensed to development partners. Its extensive portfolio currently encompasses around 70 distinct assets. The parent company, XOMA Corporation, established in 1981, has its main office in Emeryville, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free